Opinion|Videos|January 23, 2025
HER2 Key Differences and Current Approaches to Biomarker Testing
Author(s)Misako Nagasaka, MD, PhD
Panelist discusses how HER2 testing evaluates protein overexpression, gene amplification, and mutations. Although breast and gastric cancers typically show overexpression/amplification, other tumors more commonly harbor mutations.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the key differences between HER2 overexpression, amplification, and mutations across tumor types? How do these differences affect treatment selection?
- What is your current approach to biomarker testing for HER2 alterations across different tumor types?
Advertisement
Related to this article
Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
Medical oncologists, clinical pharmacists, and oncologic nurse practitioners share the presentation topics to look out for at WCLC 2026.
The interim 3-year OS rates were 71.2% with OST-HER2 vs 45.8% in historical controls in a phase 2b trial of fully resected, pulmonary metastatic osteosarcoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
2
Rusfertide Earns Category 1 NCCN Recommendation in Polycythemia Vera
3
PANXEON Liquid Biopsy Demonstrates Potential for Detecting Early Pancreatic Cancer
4
Distinguishing HER2 Mutations From Amplification in NSCLC Testing
5